Title:
NUCLEIC ACID DRUG AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/002359
Kind Code:
A1
Abstract:
The present inventors have identified antisense oligonucleotides (ASOs) which act on a p53 gene transcription product. By using these relatively short oligonucleotides, the amount of p53 mRNA can be reduced and the expression of the protein can be suppressed. These ASOs can be useful in treatment or prevention of acute kidney failure and alopecia.
More Like This:
Inventors:
NAKAMURA SHINGO (JP)
JIN LING (JP)
KAMIMURA TAKASHI (JP)
TAKATA RYOHEI (JP)
NASHIMOTO MASAYUKI (JP)
JIN LING (JP)
KAMIMURA TAKASHI (JP)
TAKATA RYOHEI (JP)
NASHIMOTO MASAYUKI (JP)
Application Number:
PCT/JP2020/025676
Publication Date:
January 07, 2021
Filing Date:
June 30, 2020
Export Citation:
Assignee:
VERITAS IN SILICO INC (JP)
International Classes:
A61K48/00; A61K31/7088; A61K31/7115; A61K31/712; A61K31/7125; A61P1/16; A61P9/00; A61P9/04; A61P13/12; A61P17/02; A61P17/14; A61P25/16; A61P25/28; A61P27/16; A61P35/00; A61P37/06; A61P39/02; C12N15/113; C12N15/12
Other References:
CACERES G. ET AL.: "TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.", PNAS, vol. 110, no. 40, 2013, pages 16127 - 16132, XP055783288
CORTES J. ET AL.: "Phase 2 Randomized Study of p53 Antisense Oligonucleotide (Cenersen) Plus Idarubicin With or Without Cytarabine in Refractory and Relapsed Acute Myeloid Leukemia.", CANCER, vol. 118, 2012, pages 418 - 427, XP055783290
PETTY RD. ET AL.: "Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 199, no. 1, 1994, pages 264 - 270, XP001016198
TAKEBA Y. ET AL.: "Irinotecan Activates p53 With Its Active Metabolite, Resulting in Human Hepatocellular Carcinoma Apoptosis.", J PHARMACOL SCI, vol. 104, 2007, pages 232 - 242, XP055783292
CERALINE J. ET AL.: "INACTIVATION OF p53 IN NORMAL HUMAN CELLS INCREASES G2/ M ARREST AND SENSITIVITY TO DNA-DAMAGING AGENTS.", INT. J. CANCER, vol. 75, 1998, pages 432 - 438, XP055783295
DMITRIEVA N. ET AL.: "p53 Protects renal inner medullary cells from hypertonic stress by restricting DNA replication.", AM J PHYSIOL RENAL PHYSIOL, vol. 281, 2001, pages F522 - F530, XP055783296
OKIBA SATOSHI ET AL: "Design of antisense oligonucleotide", FOLIA PHARMACOLOGICA JAPONICA, vol. 148, 2016, pages 100 - 104
CORTES J. ET AL.: "Phase 2 Randomized Study of p53 Antisense Oligonucleotide (Cenersen) Plus Idarubicin With or Without Cytarabine in Refractory and Relapsed Acute Myeloid Leukemia.", CANCER, vol. 118, 2012, pages 418 - 427, XP055783290
PETTY RD. ET AL.: "Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 199, no. 1, 1994, pages 264 - 270, XP001016198
TAKEBA Y. ET AL.: "Irinotecan Activates p53 With Its Active Metabolite, Resulting in Human Hepatocellular Carcinoma Apoptosis.", J PHARMACOL SCI, vol. 104, 2007, pages 232 - 242, XP055783292
CERALINE J. ET AL.: "INACTIVATION OF p53 IN NORMAL HUMAN CELLS INCREASES G2/ M ARREST AND SENSITIVITY TO DNA-DAMAGING AGENTS.", INT. J. CANCER, vol. 75, 1998, pages 432 - 438, XP055783295
DMITRIEVA N. ET AL.: "p53 Protects renal inner medullary cells from hypertonic stress by restricting DNA replication.", AM J PHYSIOL RENAL PHYSIOL, vol. 281, 2001, pages F522 - F530, XP055783296
OKIBA SATOSHI ET AL: "Design of antisense oligonucleotide", FOLIA PHARMACOLOGICA JAPONICA, vol. 148, 2016, pages 100 - 104
Attorney, Agent or Firm:
ITO, Katsuhiro et al. (JP)
Download PDF: